Acorn Biolabs Secures $11 Million Series A to Boost Access to Regenerative Medicine via Cell Preservation

Toronto-based biotechnology start-up, Acorn Biolabs, which helps customers freeze their stem cells in preparation for cell-based regenerative medicine treatments, has announced approximately $11 million CAD ($8 million USD) in Series A funding across multiple closings. Acorn plans to use this capital to expand its commercial footprint and develop cosmetic offerings.

Acorn Labs is an OBIO® member, alumnus of our BDSP™, CAAP®, H2BB™ and WiHI programs, and presented at the OBIO® Investment Summit.